<DOC>
	<DOCNO>NCT00004498</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety , feasibility , potential efficacy intravascular adenoviral vector mediate gene transfer liver adult partial ornithine transcarbamylase deficiency .</brief_summary>
	<brief_title>Phase I Study Adenoviral Vector Mediated Gene Transfer Ornithine Transcarbamylase Adults With Partial Ornithine Transcarbamylase Deficiency</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This dose escalation study . Patients undergo femoral arterial placement hepatic intraarterial catheter . Patients receive adenoviral vector mediate gene transfer intravascularly 30 minute . Cohorts 3 patient receive escalate dos adenoviral vector maximum tolerate dose determine . Patients follow 3 , 5 , 7 , 8 , 15 , 29 day , 2 month , every 3 month thereafter . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis partial ornithine transcarbamylase deficiency Female heterozygote abnormal allopurinol challenge underlie defect either N15 urea N15 glutamine OR Male childhood/adulthood onset OR Family history 2 affected child Stable least 1 month prior study Plasma ammonium level less 50 micromoles Prior/Concurrent Therapy Concurrent alternate pathway therapy control hyperammonemia allow Patient Characteristics Hepatic : No history liver disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No high level neutralize antibody adenovirus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2000</verification_date>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>ornithine transcarbamylase deficiency</keyword>
	<keyword>rare disease</keyword>
	<keyword>urea cycle disorder</keyword>
</DOC>